22,356 results match your criteria British journal of haematology[Journal]


Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.

Br J Haematol 2020 Jul 12. Epub 2020 Jul 12.

Perlmutter Cancer Center, NY Langone Health, New York, NY, USA.

Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM) has not been defined. The most appropriate delivery and dosing regimens of these therapies for patients at advanced age and frailty status is also unclear. The Myeloma XI study compared cyclophosphamide, thalidomide and dexamethasone (CTDa) to cyclophosphamide, lenalidomide and dexamethasone (CRDa) as induction therapy, followed by a maintenance randomisation between ongoing therapy with lenalidomide or observation for patients with ND-TNE-MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16945DOI Listing

Emicizumab treatment and monitoring in a paediatric cohort: real-world data.

Br J Haematol 2020 Jul 12. Epub 2020 Jul 12.

National Hemophilia Center, Sheba Medical Center, Tel Hashomer, Israel.

Real-world data on emicizumab use and monitoring in paediatric severe haemophilia A (HA) patients are scarce. We therefore sought to evaluate safety, efficacy, and laboratory monitoring of emicizumab prophylaxis in a cohort of 40 children with severe HA, including 22 non-inhibitor patients and nine infants younger than one year. Bleeding, trauma, adverse events, and surgeries were documented during a median follow-up of 45 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16964DOI Listing

Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy.

Authors:
Rick Kapur

Br J Haematol 2020 Jul 12. Epub 2020 Jul 12.

Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16958DOI Listing

Assessing the risk of refractory disease in iTTP.

Br J Haematol 2020 Jul 12. Epub 2020 Jul 12.

Blood Transfusion Service, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16947DOI Listing

Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study.

Br J Haematol 2020 Jul 11. Epub 2020 Jul 11.

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.

Aberrant blood cell counts, most prominently lymphopenia, have been identified as markers of the degree of severity of coronavirus disease 2019 (COVID-19) (Terpos et al, 2020; Yang et al, 2020; Wan et al, 2020; Wang et al, 2020; Zhao et al, 2020). However, most of these studies lack comparison to a COVID-19 negative, contemporary control group. Additionally, the longitudinal composition and dynamics of lymphocyte subsets in COVID-19 patients are insufficiently characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16983DOI Listing

Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.

Br J Haematol 2020 Jul 11. Epub 2020 Jul 11.

Department of Haematology, Great Ormond Street Hospital for Children NHS Trust, London, UK.

The COVID-19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS-CoV-2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17014DOI Listing

Varying Presentations and Favourable Outcomes of COVID-19 Infection in Children and Young Adults with Sickle Cell Disease: An Additional Case Series with Comparisons to Published Cases.

Br J Haematol 2020 Jul 11. Epub 2020 Jul 11.

Divisions of Hematology/ Oncology and Cellular Therapy, Cohen Children's Medical Center, New York, NY, 11040, United States.

Patients with sickle cell disease (SCD) are theoretically at greater risk for serious illness from COVID 19 due to the underlying pathophysiology of chronic inflammation with an increased risk of thrombosis, especially at the time of a vaso-occlusive event (1). Individuals living with SCD are also considered to be immunocompromised due to autoinfarction of their spleen or surgical splenectomy, often as a result of red cell splenic sequestration (2). In addition, patients with SCD often have comorbidities and secondary organ dysfunction that can put them at risk of significant morbidity and or mortality from the severe acute respiratory coronavirus 2 (SARS-CoV-2), and its subsequent disease COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17013DOI Listing

Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.

Br J Haematol 2020 Jul 9. Epub 2020 Jul 9.

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.

Relapses involving the central nervous system (CNS) are rare in children and adolescents with ALK+ anaplastic large cell lymphoma (ALCL) treated with regimens including CNS prophylaxis. Early identification of patients at high-risk for CNS relapse would enable stratification and better adaptation of initial treatment especially in the light of the upcoming targeted therapies with limited CNS penetration. We analyzed clinical and histological data of all ALK+ALCL patients with CNS relapse registered in ALCL99-database with the aim to describe risk factors and outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16755DOI Listing

COVID-19 comorbidities, associated pro-coagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?

Authors:
Jameel Inal

Br J Haematol 2020 Jul 9. Epub 2020 Jul 9.

School of Human Sciences, London Metropolitan University, London, U.K.

Several comorbidities predict mortality in patients with COVID-19, some of which are more prevalent in Black Asian and Minority Ethnic (BAME) groups. Extracellular vesicles (EVs) released from cells are nano-sized membrane-bound vesicles that carry nucleic acids and proteins and mediate intercellular communication. In COVID-19 associated comorbidities including diabetes, CVD and risk factors such as hypertension, elevated angiotensin II and obesity, levels of circulating EVs are raised and their cargo modified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17011DOI Listing

Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.

Authors:
Lúcia Silla

Br J Haematol 2020 Jul 9. Epub 2020 Jul 9.

Hospital de Clínicas, Hematologia e Hemoterapia, Porto Alegre, RS, Brazil.

SARS-CoV-2, affecting predominantly elderlies, was recognized as a global pandemic in March 11 , 2020; clinical signs and laboratory alterations are similar to previous coronavirus epidemics with lymphocytopenia and neutrophilia observed in severe cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17010DOI Listing

GATA2 deficiency in a young man with lymphoedema.

Br J Haematol 2020 Jul 9. Epub 2020 Jul 9.

Blood and Cancer Centre, Wellington Regional Hospital, Wellington, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16941DOI Listing

Progress in treating chronic granulomatous disease.

Authors:
Andrew R Gennery

Br J Haematol 2020 Jul 8. Epub 2020 Jul 8.

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Chronic granulomatous disease is a primary immunodeficiency due to a defect in one of six subunits that make up the nicotinamide adenine dinucleotide phosphate oxidase complex. The most commonly defective protein, gp91 , is inherited in an X-linked fashion; other defects have autosomal recessive inheritance. Bacterial and fungal infections are common presentations, although inflammatory complications are increasingly recognized as a significant cause of morbidity and are challenging to treat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16939DOI Listing

CoVID-19 insights from transfusion medicine.

Authors:
Willy A Flegel

Br J Haematol 2020 Jul 8. Epub 2020 Jul 8.

Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.

The emergence of CoVID-19 infection in the first months of 2020 resulted in a massive surge in admissions to hospitals and intensive care units due to the nature of the respiratory pathophysiology. In some countries, health care systems were rapidly overwhelmed, while in others their hospitals coped with the first wave and all patients received the level of care needed, depending upon both the containment measured and the level of development of the heath care systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17005DOI Listing

Blood Component Use in Critical Care in Patients with COVID-19 Infection: A Single Centre Experience.

Br J Haematol 2020 Jul 8. Epub 2020 Jul 8.

Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.

There has been a significant surge in admissions to critical care during the COVID-19 pandemic. At present, the demands on blood components have not been described. We reviewed their use during the first 6 weeks of the outbreak from 3 March 2020 in a tertiary-level critical care department providing veno-venous extracorporeal membrane oxygenation (vv-ECMO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.17007DOI Listing

High prevalence of peripheral lymphopenia in Langerhans cell histiocytosis.

Br J Haematol 2020 Jul 8. Epub 2020 Jul 8.

Department of Women's and Children's Health, Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16923DOI Listing

T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.

Br J Haematol 2020 Jul 7. Epub 2020 Jul 7.

Vanderbilt University Medical Centre, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16929DOI Listing

Rapid diagnosis of hereditary haemolytic anaemias using automated rheoscopy and supervised machine learning.

Br J Haematol 2020 Jul 5. Epub 2020 Jul 5.

School of Biochemistry, University of Bristol, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16868DOI Listing

Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: Methodological issues and clinical implications.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.

COVID-19 is associated with increased risk of venous thromboembolic events (VTE). However, there is significant heterogeneity in the thromboembolic phenotypes of COVID-19 patients (deep vein thrombosis, pulmonary embolism/thrombosis). The latter might be partly attributed to the variation in VTE risk factors in COVID-19 patients including: (i) patients' characteristics; (ii) hospitalization conditions and interventions; (iii) SARS-Cov-2 specific factors (coagulopathy, endothelial injury/microthrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16993DOI Listing

COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

GIMEMA Foundation, Franco Mandelli Onlus, Rome, Italy.

With the outbreak of COVID-19 pandemic (Wang et al, 2020), Italy - and in particular the largest Northern regions - became disease epicenter with a dramatic raise in infections and deaths in the month of March. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16996DOI Listing

Cumulative outcome of pre-implantation genetic diagnosis for sickle cell disease: a 5-year review.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

Department of Obstetrics and Gynaecology, Assisted Conception Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.

To review the cumulative outcome of pre-implantation genetic diagnosis (PGD) cycles performed for prevention of sickle cell disease (SCD). Couples referred for PGD for SCD between April 2012 and October 2017 were included. Ovarian stimulation was performed using a short gonadotrophin-releasing hormone (GnRH) antagonist protocol and follicle-stimulating hormone injections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16930DOI Listing
July 2020
4.711 Impact Factor

FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK.

The UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post-cycle-2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16875DOI Listing

Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.

Br J Haematol 2020 Jul 4. Epub 2020 Jul 4.

Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.

Fluconazole is one of the most commonly used drugs for antifungal prophylaxis in childhood leukaemia. However, its interaction with vincristine may induce neuropathy and the emergence of antifungal drug resistance contributes to substantial mortality caused by invasive fungal infections (IFIs). In a retrospective single-centre study, we compared tolerability and outcome of different antifungal prophylaxis strategies in 198 children with acute leukaemia (median age 5·3 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16931DOI Listing

Molecular testing of chronic myeloid leukaemia in low resource areas.

Authors:
Jerald Radich

Br J Haematol 2020 Jul 3. Epub 2020 Jul 3.

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Most cancer cases occur in areas of low resources. The diagnosis, treatment and monitoring of cancers is especially challenging in these locations. Unique partnerships exist between non-profit organisations and pharmaceutical companies to provide free drugs to CML patients throughout the world if the diagnosis can be rigorously and unambiguously established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16894DOI Listing

Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.

Br J Haematol 2020 Jul 2. Epub 2020 Jul 2.

Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16921DOI Listing
July 2020
4.711 Impact Factor

Cabot rings and other peripheral blood features of Imerslund-Gräsbeck syndrome.

Br J Haematol 2020 Jul 2. Epub 2020 Jul 2.

Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16933DOI Listing

Concerns about how to use established minimal residual disease (MRD) monitoring in the treatment of NPM1-mutant AML following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.

Br J Haematol 2020 Jul 1. Epub 2020 Jul 1.

Department of Haematology, University College Hospitals NHS Foundation Trust, London, United Kingdom.

In view of the COVID-19 pandemic and the predicted risk of severe infection in immunocompromised patients, chemotherapy protocols for patients with Acute Myeloid Leukaemia (AML) have been modified in some patients to newer, less myelosuppressive regimens than standard induction chemotherapy. However, the modifications to treatment have occurred at such a considerable pace due to the urgency of the pandemic, that optimal time points for measuring minimal residual disease (MRD) to assess disease response and monitor for relapse have not yet been established for the new regimens. Thus, decisions about duration of therapy and appropriate timepoints to intensify therapy prove very challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16985DOI Listing

ABO Phenotype and Death in Critically Ill Patients with COVID-19.

Br J Haematol 2020 Jul 1. Epub 2020 Jul 1.

Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Blood groups are inherited traits that vary across populations, likely due to both founder effects and natural selection. A link between blood groups and susceptibility to infectious disease has been well-described, with notable examples being H. Pylori and Plasmodium falciparum infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16984DOI Listing

Epigenetic targeting in lymphoma.

Br J Haematol 2020 Jul 1. Epub 2020 Jul 1.

Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Despite considerable progress in the treatment of patients with lymphoid malignancies in recent decades, the prognosis of patients with relapsed or refractory lymphomas often remains disappointing. Increasing evidence has established the relevance of epigenetic alterations in the pathogenesis of lymphoid malignancies, and a succession of agents has been evaluated in clinical studies with varying efficacy. In the present review, we outline the importance of epigenetic modifications in lymphoma biology and discuss the published experience with epigenetic modifying agents by lymphoma subtype before considering ongoing clinical studies in this area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16914DOI Listing

A stitch in time saves nine… MRD-based pre-emptive therapy.

Br J Haematol 2020 Jun 30. Epub 2020 Jun 30.

Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16913DOI Listing

'MPN Genomic Calculator': real-life use in a young population with essential thrombocythaemia.

Br J Haematol 2020 Jun 30. Epub 2020 Jun 30.

Institut de Cancéro-Hématologie, Hématologie Clinique, CHRU de Brest, Brest, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16924DOI Listing

Machine learning and artificial intelligence in haematology.

Br J Haematol 2020 Jun 30. Epub 2020 Jun 30.

Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Digitalization of the medical record and integration of genomic methods into clinical practice have resulted in an unprecedented wealth of data. Machine learning is a subdomain of artificial intelligence that attempts to computationally extract meaningful insights from complex data structures. Applications of machine learning in haematological scenarios are steadily increasing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16915DOI Listing

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.

Br J Haematol 2020 Jun 29. Epub 2020 Jun 29.

Oregon Health and Science University, Portland, OR, USA.

Comorbidities influence survival in patients with chronic lymphocytic leukaemia (CLL) treated with chemo-immunotherapy or ibrutinib. While idelalisib has been studied in patients with comorbidities, their impact has not been investigated. We analysed 481 patients treated with idelalisib on two randomised trials (NCT01659021 and NCT01539512). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16879DOI Listing

Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.

Br J Haematol 2020 Jun 27. Epub 2020 Jun 27.

General Intensive Care Unit, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton.

On 30th March 2020, a 57-year-old male patient presented to the Emergency Department with a 6-day history of cough, persistent fevers and worsening dyspnoea. His only known comorbidity was hypertension, managed with amlodipine and an angiotensin converting enzyme inhibitor. On admission, he was tachypnoeic and in severe hypoxic respiratory failure with dangerously low peripheral oxygen saturations (SpO ) 83% on 15L oxygen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16978DOI Listing

Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.

Br J Haematol 2020 Jun 27. Epub 2020 Jun 27.

Centre for Haematology, Department of Immunology & Inflammation, Imperial College London, London, UK.

Whilst the majority of patients with COVID-19 infection have mild self-limiting symptoms, for some the SARS-CoV2 virus can trigger a severe hyperinflammatory syndrome which is life threatening. Anti-IL6 therapy has shown promise in restraining the hyperinflammatory syndrome and while IL-6 is a pleiotropic mediatory of the inflammatory response, redundancy within inflammatory pathways means that the use of such targeted monoclonal therapy may have too restricted a repertoire in some patients. We present the case of a 53-year-old haematopoetic stem cell transplant recipient who developed a severe COVID-19 that was refractory to anti-IL6 therapy, but responded to Jak-Stat inhibition with ruxolitinib, demonstrating its safety and efficacy in this setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16979DOI Listing

Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery.

Br J Haematol 2020 Jun 27. Epub 2020 Jun 27.

Tropical and Infectious Diseases, University Hospital, Montpellier cedex, France.

We read with deep interest the report by Tepasse and colleagues , concerning two cases of persisting viremia in Covid-19 with fatal outcome. Whilst SARS-CoV-2 infection in the early stages of infection has been well described, less is known about the development of antibodies to SARS-CoV-2, clearance of RNA shedding and clinical outcome of COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16981DOI Listing

The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

No consensus has been reached on the relationship between CBFB-MYH11 copies and prognosis. Of 1525 acute myeloid leukemia (AML) patients, 58 with CBFB-MYH11-positive AML (16/58 patients with c-kit mutation) were retrospectively analyzed with a median follow-up duration of 29.8 (range: 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16745DOI Listing
June 2020
4.711 Impact Factor

Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Next-generation sequencing (NGS) increasingly influences diagnosis, prognosis and management of myelodysplastic syndrome (MDS). In addition to marrow morphology and flow cytometry, our institution performs cytogenetics (CG) and NGS-based testing routinely in patients with suspected MDS. We evaluated the relative value of NGS in the assessment of patients with suspected MDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16891DOI Listing

COVID-19 mortality in patients on anticoagulants and antiplatelet agents.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Brighton and Sussex Medical School, University of Sussex, Brighton, UK.

Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D-dimer and fibrinogen levels (Al-Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID-19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID-19 (Klok, et al 2020, Stoneham, et al). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16968DOI Listing

Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Royal Berkshire Hospital NHS Foundation Trust, Reading, United Kingdom.

Coronavirus disease 2019 (COVID-19), caused by novel SARS-CoV-2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. (1,2) Severe COVID-19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. (3,4) There is emerging evidence for the use of an interleukin 6 (IL-6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16966DOI Listing

Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Department of Haematology, University College London Hospital (UCLH), 3rd Floor West, 250 Euston Road, London, UK, NW1 2PG.

The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/COVID-19 is unknown. We report the case of a previously fit 27-year-old male who presented with a 3-day history of fever (>39 C), swollen, erythematous elbows and no respiratory symptoms. His white blood count (WBC) was 187×10 /L and bone marrow (Figure 1A & 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild-type NPM1 and no additional mutations on a next-generation sequencing panel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16962DOI Listing

Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.

Br J Haematol 2020 Jun 25. Epub 2020 Jun 25.

Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16961DOI Listing
June 2020
4.711 Impact Factor

Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.

Br J Haematol 2020 Jun 24. Epub 2020 Jun 24.

Department of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.

Primary objective of this non-interventional, post-authorisation safety study was to provide real-world safety data [incidence of adverse drug reactions (ADRs)/serious adverse events (SAEs)] on adult patients with myelofibrosis exposed/or not exposed to ruxolitinib. Key secondary objectives included the incidence/outcome of events of special interest (bleeding events, serious/opportunistic infections, second primary malignancies, and deaths). Overall, 462 patients were included [prevalent users = 260, new users = 32, non-exposed = 170 (inclusive of ruxolitinib-switch, n = 57)]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16729DOI Listing

Regulatory cells in immune-mediated aplastic anaemia - not T but B.

Br J Haematol 2020 Jun 4. Epub 2020 Jun 4.

Department of Haematological Medicine, King's College Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16713DOI Listing

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).

Br J Haematol 2020 Jun 24. Epub 2020 Jun 24.

Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16878DOI Listing